Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy

Abstract Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the lysosomal enzyme, α‐galactosidase. Gb3 deposits activate immune‐mediated systemic inflammation, ultimately leading to life‐threatening co...

Full description

Bibliographic Details
Main Authors: Li Fu, Sylwia Wasiak, Laura M. Tsujikawa, Brooke D. Rakai, Stephanie C. Stotz, Norman C. W. Wong, Jan O. Johansson, Michael Sweeney, Connie M. Mohan, Aneal Khan, Ewelina Kulikowski
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Pharmacology Research & Perspectives
Subjects:
apabetalone
BETi
epigenetics
Fabry disease
inflammation
oxidative stress
Online Access:https://doi.org/10.1002/prp2.949

Internet

https://doi.org/10.1002/prp2.949

Similar Items